title: In vitro bio-immunological and cytotoxicity studies of poly(2-oxazolines).
abstract: Poly(2-oxazolines) with varying alkyl chain lengths (e.g., methyl, ethyl, aryl) and molar masses have been tested for cell cytotoxicity in vitro. A standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used for the estimation of cell viability. Two monomers, 2-methyl-2-oxazoline and 2-ethyl-2-oxazoline, were found to provide polymers with non-cytotoxic properties. The dependence of cell viability on molar mass confirmed the expected trend; the viability increased with the higher molar mass of poly(2-ethyl-2-oxazoline) (PETOX), up to 15,000 g/mol. The results obtained for the polymers with aliphatic side chains were compared with the analogues that possessed an aromatic moiety. All results confirmed low cytotoxicity of the polymers prepared by cationic polymerization of 2-alkyl- and 2-aryl-2-oxazolines, which supports their utilization in biomedical applications. Fluorescence microscopy and steady-state fluorescence were used to observe pyrene-labeled polymer interactions with living cells. Polymer accumulated within the cells was found to be dependent on polymer concentration in media. The immunoefficiency of aromatic and aliphatic oxazoline polymers and copolymers was also studied. Phagocytic and metabolic activities of macrophages were used to assess the immunosuppressive effects of the selected copolymers for possible applications in drug delivery and immunobiology. Overall, the tested polymers demonstrated no significant influences on the cellular immunological parameters.
authors: Polymer Institute, Slovak Academy of Sciences, Centre of Excellence GLYCOMED, Dúbravská cesta 9, 84541 Bratislava, Slovakia. upolkron@savba.sk
authors: Juraj
authors: J
authors: Kronek
authors: Zuzana
authors: Z
authors: Kroneková
authors: Jozef
authors: J
authors: Lustoň
authors: Ema
authors: E
authors: Paulovičová
authors: Lucia
authors: L
authors: Paulovičová
authors: Barbara
authors: B
authors: Mendrek
references: J Control Release. 2003 May 20;89(3):437-46
references: 12737846
references: J Control Release. 2007 Jun 22;119(3):291-300
references: 17451833
references: Adv Drug Deliv Rev. 2007 Dec 22;59(15):1504-20
references: 17904246
references: Trends Biotechnol. 2002 Jul;20(7):305-11
references: 12062976
references: Eur J Med Chem. 2010 Feb;45(2):795-9
references: 19939517
references: Eur J Haematol Suppl. 1996;60:111-8
references: 8987252
references: Immunity. 2005 May;22(5):539-50
references: 15894272
references: Biomaterials. 2010 Jun;31(18):4972-9
references: 20346493
references: Macromol Rapid Commun. 2010 Nov 1;31(21):1869-73
references: 21567605
references: J Mater Sci Mater Med. 2010 Mar;21(3):879-86
references: 19957102
references: Mol Pharmacol. 1997 Aug;52(2):323-34
references: 9271356
references: Chem Biol. 2003 Dec;10(12):1161-71
references: 14700624
references: Biochem Pharmacol. 1987 Dec 1;36(23):4181-5
references: 3689447
references: J Control Release. 2008 Jan 22;125(2):87-95
references: 18031860
references: Eur J Immunol. 2007 Nov;37 Suppl 1:S9-17
references: 17972350
references: J Control Release. 2008 May 8;127(3):189-207
references: 18321604
references: J Control Release. 2001 Jun 15;73(2-3):391-9
references: 11516514